Form 4: Acumen Pharma CRO Granted Significant Equity Awards

Acumen Pharmaceuticals' Chief Regulatory Officer, Amy Schacterle, received significant equity awards including restricted stock units and stock options.

Summary

• Amy Schacterle, Chief Regulatory Officer of Acumen Pharmaceuticals, Inc. (ABOS), was granted 84,600 Restricted Stock Units (RSUs) on January 16, 2026.
• Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, with a grant price of $0.
• The RSUs will vest in three equal annual installments, commencing one year after the grant date, contingent on continuous service.
• Following the RSU transaction, Ms. Schacterle beneficially owns 92,303 shares of Common Stock.
• Ms. Schacterle was also granted Employee Stock Options to purchase 126,900 shares of Common Stock on January 16, 2026.
• The exercise price for these options is $1.89 per share, and the grant price was $0.
• These options will vest in 48 equal monthly installments, becoming fully vested on the fourth anniversary of the grant date, subject to continuous service.
• The options have an expiration date of January 16, 2036.
• Following the option transaction, Ms. Schacterle beneficially owns 126,900 derivative securities (options).

Sentiment

Score: 7

Explanation: The filing reports routine executive compensation, which is generally positive as it aligns management incentives with shareholder interests. It does not contain new operational or financial performance data, hence a moderately positive score reflecting standard corporate governance practice.

Positives

• The grant of equity awards to a key executive, Amy Schacterle, aligns her long-term interests with those of shareholders, incentivizing sustained performance and value creation.
• The awards represent a standard practice in executive compensation, indicating a commitment to retaining and motivating key talent.

Future Outlook

The equity awards are structured with multi-year vesting schedules, indicating a long-term incentive for the Chief Regulatory Officer, Amy Schacterle, to remain with Acumen Pharmaceuticals and contribute to its future success. The vesting of RSUs will commence one year after the grant date, and options will vest monthly over four years.

Industry Context

Equity compensation, such as Restricted Stock Units and stock options, is a common and standard practice across the biotechnology and pharmaceutical industries. It serves as a critical tool for attracting, retaining, and motivating key executives by aligning their financial interests with the long-term performance of the company and its shareholders.

Comparison to Industry Standards

• The structure of these equity awards, including multi-year vesting schedules for both RSUs and stock options, is consistent with typical executive compensation packages observed in the biotechnology sector.
• The use of both RSUs (which provide value even if the stock price declines, albeit less) and stock options (which provide upside leverage) is a common strategy to offer balanced incentives to executives.

Corporate Governance

Related Party Transactions

• The equity awards granted to Amy Schacterle, Chief Regulatory Officer, constitute a related party transaction as she is an executive officer of Acumen Pharmaceuticals, Inc. This is a standard compensation practice.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of executive incentives with long-term company performance and shareholder value creation.
• Employees (specifically the reporting person): Positive impact through significant equity compensation, enhancing personal wealth potential and job satisfaction.

Next Steps

• The RSUs will begin vesting in three equal annual installments, commencing one year after the grant date of January 16, 2026.
• The Employee Stock Options will vest in 48 equal monthly installments, with full vesting on the fourth anniversary of the grant date of January 16, 2026.

Key Dates

Recommendation

This Form 4 reports routine equity compensation for a key executive, which is a standard practice to align management incentives with shareholder interests. It does not contain new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Investors should continue to monitor the company's fundamental performance and broader market conditions.

Keywords

Acumen Pharmaceuticals, ABOS, Form 4, Insider Transaction, Equity Award, Restricted Stock Units, Stock Options, Executive Compensation, Amy Schacterle, Chief Regulatory Officer